Treatment Approaches for Patients With EGFR-Mutant NSCLC

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.

Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.